RxSight (RXST) Competitors $8.80 +0.24 (+2.80%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.80 -0.01 (-0.06%) As of 10/3/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. CDRE, NVCR, CNMD, KMTS, PLSE, BLFS, ESTA, SSII, MDXG, and INMDShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Cadre (CDRE), NovoCure (NVCR), CONMED (CNMD), Kestra Medical Technologies (KMTS), Pulse Biosciences (PLSE), BioLife Solutions (BLFS), Establishment Labs (ESTA), SS Innovations International (SSII), MiMedx Group (MDXG), and InMode (INMD). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors Cadre NovoCure CONMED Kestra Medical Technologies Pulse Biosciences BioLife Solutions Establishment Labs SS Innovations International MiMedx Group InMode RxSight (NASDAQ:RXST) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk. Is RXST or CDRE more profitable? Cadre has a net margin of 6.65% compared to RxSight's net margin of -21.93%. Cadre's return on equity of 12.08% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-21.93% -11.56% -10.31% Cadre 6.65%12.08%5.60% Does the media refer more to RXST or CDRE? In the previous week, Cadre had 3 more articles in the media than RxSight. MarketBeat recorded 3 mentions for Cadre and 0 mentions for RxSight. RxSight's average media sentiment score of 0.00 beat Cadre's score of -0.05 indicating that RxSight is being referred to more favorably in the media. Company Overall Sentiment RxSight Neutral Cadre Neutral Do analysts recommend RXST or CDRE? RxSight currently has a consensus target price of $10.00, indicating a potential upside of 13.64%. Cadre has a consensus target price of $31.50, indicating a potential downside of 14.26%. Given RxSight's higher possible upside, equities analysts plainly believe RxSight is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 3 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.85Cadre 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, RXST or CDRE? Cadre has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M2.57-$27.45M-$0.80-11.00Cadre$567.56M2.63$36.13M$0.9439.09 Do insiders & institutionals believe in RXST or CDRE? 78.8% of RxSight shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 31.5% of Cadre shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, RXST or CDRE? RxSight has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. SummaryCadre beats RxSight on 12 of the 15 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$350.24M$6.88B$6.05B$10.58BDividend YieldN/A1.18%5.68%4.69%P/E Ratio-11.0026.9977.3326.67Price / Sales2.57199.27606.38133.73Price / CashN/A21.7737.7361.25Price / Book1.265.3012.556.55Net Income-$27.45M$178.07M$3.30B$277.26M7 Day Performance-2.55%5.15%28,056.13%2.37%1 Month Performance3.90%11.08%28,993.65%9.30%1 Year Performance-82.00%28.77%35,460.84%30.78% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight1.9515 of 5 stars$8.80+2.8%$10.00+13.6%-81.6%$350.24M$139.93M-11.00220CDRECadre2.2412 of 5 stars$36.06-0.8%$31.50-12.6%-2.6%$1.48B$567.56M38.362,284NVCRNovoCure4.3019 of 5 stars$12.92+0.2%$28.79+122.8%+0.8%$1.44B$605.22M-8.281,488Analyst ForecastCNMDCONMED4.6807 of 5 stars$45.64-0.8%$59.80+31.0%-27.7%$1.42B$1.31B12.933,900News CoverageKMTSKestra Medical Technologies1.0325 of 5 stars$23.41-3.8%$27.33+16.8%N/A$1.25B$66.40M0.00300Gap DownPLSEPulse Biosciences3.5559 of 5 stars$17.80+0.2%$22.00+23.6%+19.8%$1.20B$700K-16.95140BLFSBioLife Solutions2.6048 of 5 stars$24.52-0.7%$31.29+27.6%+9.3%$1.18B$93.47M-204.32440ESTAEstablishment Labs2.9849 of 5 stars$41.37+5.8%$56.50+36.6%-0.9%$1.13B$166.02M-13.561,018SSIISS Innovations InternationalN/A$5.65+1.6%N/AN/A$1.08B$20.65M0.004News CoverageGap DownMDXGMiMedx Group2.881 of 5 stars$6.93-0.1%$12.00+73.2%+26.0%$1.03B$348.88M33.00870INMDInMode3.1037 of 5 stars$15.00+0.7%$18.04+20.3%-0.2%$941.81M$401.56M6.07480 Related Companies and Tools Related Companies Cadre Alternatives NovoCure Alternatives CONMED Alternatives Kestra Medical Technologies Alternatives Pulse Biosciences Alternatives BioLife Solutions Alternatives Establishment Labs Alternatives SS Innovations International Alternatives MiMedx Group Alternatives InMode Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
